Semaglutide: Oral GLP-1 Receptor Analogue

Abstract

Semaglutide seems to be a promising option for early and later stages of diabetes treatment, it is a first-in-class oral GLP-1RA and has shown up to a 1.5 % reduction in HbA1c across PIONEER trials. Semaglutide could be a revolutionary option for the management of diabetes, being the most efficacious profile of oral diabetics known along with the convenience of oral administration.